|

Apixaban 2.5 mg twice daily Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 3: 1

Top Sponsors

  • University of Vermont1

Indications

  • VTE (Venous Thromboembolism)1
  • Cancer1

Burlington, Vermont1 trial

DOAC - Dosing Options in AntiCoagulation Prophylaxis

University of Vermont Medical Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.